This investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously is being studied for obesity and type 2 diabetes management, with early-phase data showing promising results
Consuming calorie-dense, nutrient-poor meals can diminish the weight management benefits of GLP-1 drugs, even though the medication continues to function at a molecular level
The sign-in flow should reduce friction, while still preserving essential safeguards
Semaglutide also suppresses glucagon secretion
It is not intended for human or veterinary use, diagnosis, treatment, or prevention of any disease
Regular monitoring is a cornerstone of our approach